Chong Kun Dang Pharmaceutical Corp.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Public

Established: 1941-01-01

Employees: 2.3K

Market Cap: -

Website: http://www.ckdpharm.com

Clinical Trials

A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355

Phase 1

Completed

Conditions: Alzheimer's Disease (AD)

Interventions: Drug: CKD-355A (D797/Memantine HCl 20mg)
Drug: CKD-355B (D797/Memantine HCl 20mg)
Drug: D797
Drug: D324 (Memantine HCl 10mg)

First Posted Date: 2019-01-14

Last Posted Date: 2019-10-23

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 60

Registration Number: NCT03802162

Locations: 🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of

Impact of Lymphocyte Anti-metabolite Immunosuppressions on Donor-Specific Anti-HLA Antibody and Kidney Graft Outcome

Phase 4

Completed

Conditions: Kidney Transplant

Interventions: Drug: Mycophenolate mofetil 500mg Tab. or 250mg Cap.
Drug: Tacrolimus
Drug: Methylprednisolone/prednisolone
Drug: Basiliximab

First Posted Date: 2019-01-07

Last Posted Date: 2024-05-22

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 169

Registration Number: NCT03794492

Locations: 🇰🇷
Ajou University Hospital, Suwan, Korea, Republic of

Compare the Pharmacokinetics and Safety of CKD-391 With Co-administration of D086 and D337

Phase 1

Completed

Conditions: Hyperlipidemias

Interventions: Drug: T
Drug: R

First Posted Date: 2019-01-04

Last Posted Date: 2019-01-07

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 45

Registration Number: NCT03793985

Locations: 🇰🇷
INHA University Hospital, Incheon, Korea, Republic of

A Clinical Study to Evaluate the Efficacy and Safety of CKD-351

Phase 3

Conditions: Primary Open-angle Glaucoma
Ocular Hypertension

Interventions: Drug: CKD-351
Drug: Latanoprost
Drug: D930
Drug: Placebo of CKD-351
Drug: Placebo of D930

First Posted Date: 2018-12-03

Last Posted Date: 2018-12-03

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 384

Registration Number: NCT03762369

Locations: 🇰🇷
Seoul National University Hosipital, Seoul, Jongno, Korea, Republic of

Study to Evaluate the Efficacy and Safety of Once-Daily Tacrolimus in Kidney Transplant Recipients

Phase 4

Completed

Conditions: Kidney Transplant

Interventions: Drug: TacroBell SR cap.

First Posted Date: 2018-11-21

Last Posted Date: 2021-01-05

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 141

Registration Number: NCT03749356

Locations: 🇰🇷
Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of

Clinical Trial to Evaluate Pharmacokinetic Profiles and Safety Between CKD-385 and D935 in Healthy Volunteers

Phase 1

Conditions: Hypertension

Interventions: Drug: D935 Cap. 1T
Drug: CKD-385 Tab. 1T

First Posted Date: 2018-11-20

Last Posted Date: 2018-12-31

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 52

Registration Number: NCT03748212

Locations: 🇰🇷
Chonbuk National University Hospital, Jeonju, Korea, Republic of

The Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-387 Under Fed Condition

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: CKD-387
Drug: D484

First Posted Date: 2018-11-13

Last Posted Date: 2019-02-21

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 23

Registration Number: NCT03738449

Locations: 🇰🇷
Severance Hospital, Seoul, Korea, Republic of

Efficacy and Safety of CKD-501 Added to D150 Plus D745 10mg Therapy in Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Type2 Diabetes

Interventions: Drug: Placebo
Drug: CKD-501 0.5mg

First Posted Date: 2018-11-13

Last Posted Date: 2021-08-25

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 226

Registration Number: NCT03739125

Locations: 🇰🇷
Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of

The Clinical Trial to Evaluate the Efficacy and Safety of CKD-497

Phase 2

Completed

Conditions: Respiratory Infection

Interventions: Drug: CKD-497 200mg
Drug: CKD-497 300mg
Drug: CKD-497 placebo
Drug: Comparator placebo
Drug: Comparator

First Posted Date: 2018-11-01

Last Posted Date: 2020-02-06

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 220

Registration Number: NCT03726853

Locations: 🇰🇷
Korea University Anam hospital, Seoul, Seongbuk-gu, Korea, Republic of
🇰🇷
Kangbuk Samsung Hospital, Seoul, Jongno-gu, Korea, Republic of
🇰🇷
Hallym University Sacred Heart Hospital, Anyang, Gyeonggi-do, Korea, Republic of

and more 12 locations

A Study to Investigate Drug-Drug Interaction Between D326, D337 and CKD-828 in Healthy Subjects

Phase 1

Conditions: Dyslipidemias
Hypertension

Interventions: Drug: Sequence 1
Drug: Sequence 2
Drug: Sequence 3
Drug: Sequence 4
Drug: Sequence 5
Drug: Sequence 6

First Posted Date: 2018-11-01

Last Posted Date: 2018-11-01

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 30

Registration Number: NCT03726866

Locations: 🇰🇷
Asan Medical Center, University of Ulsan, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy